Role of cullin-elonginB-elonginC E3 complex in bovine immunodeficiency virus and maedi-visna virus Vif-mediated degradation of host A3Z2-Z3 proteins

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Zhang, Jingyao ^a   Wu, Jiaxin ^a,b   Wang, Weiran ^a   Wu, Hui ^a,b   Yu, Bin ^a,b   Wang, Jiawen ^a   Lv, Mingyu ^a   Wang, Xiaodan ^a   Zhang, Haihong ^a,b   Kong, Wei ^a,b   Yu, Xianghui ^a,b  

^a National Engineering Laboratoty of AIDS Vaccine   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

BIV Vif; CCHC motif; E3 ubiquitin ligase; MVV Vif

Indexed keywords

A3Z2 Z3; CHELATING AGENT; CULLIN; ELONGIN B; ELONGIN C; SUPPRESSOR OF CYTOKINE SIGNALING; TPEN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS PROTEIN; APOBEC3 PROTEIN, HUMAN; CYTOSINE DEAMINASE; ELONGIN; PROTEASOME; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; BOS TAURUS; BOVINE IMMUNODEFICIENCY LIKE VIRUS; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; DOMESTIC SHEEP; GENE MUTATION; HYDROPHILICITY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SPECIES DIFFERENCE; VIRUS CELL INTERACTION; VISNA VIRUS; ANIMAL; CHEMISTRY; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY;

BOVINE IMMUNODEFICIENCY VIRUS; VISNA/MAEDI VIRUS;

ANIMALS; CULLIN PROTEINS; CYTOSINE DEAMINASE; GENE PRODUCTS, VIF; HEK293 CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNODEFICIENCY VIRUS, BOVINE; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; VISNA-MAEDI VIRUS;

EID: 84908095960     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0077-9     Document Type: Article

References (52)

1. Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987, 237(4817):888-893. 10.1126/science.3497453, 3497453.
2. Ehrlich ES, Yu XF. Lentiviral Vif: viral hijacker of the ubiquitin-proteasome system. Int J Hematol 2006, 83(3):208-212. 10.1532/IJH97.06013, 16720549.
3. Romani B, Engelbrecht S, Glashoff RH. Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif. Arch Virol 2009, 154(10):1579-1588. 10.1007/s00705-009-0481-y, 19669862.
4. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418(6898):646-650. 10.1038/nature00939, 12167863.
5. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing?. Trends Biochem Sci 2007, 32(3):118-128. 10.1016/j.tibs.2007.01.004, 17303427.
6. Yu XF. Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses. Curr Opin HIV AIDS 2006, 1(3):187-193. 10.1097/01.COH.0000221590.03670.32, 19372807.
7. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 2004, 4(11):868-877. 10.1038/nri1489, 15516966.
8. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113(6):803-809. 10.1016/S0092-8674(03)00423-9, 12809610.
9. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 2004, 279(34):35822-35828. 10.1074/jbc.M405761200, 15210704.
10. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, Trabattoni D, Naddeo V, Lopalco L, Clivio A, Cesana E, Fasano F, Bergamaschi C, Mazzotta F, Miyazawa M, Clerici M. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 2007, 195(7):960-964. 10.1086/511988, 17330785.
11. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 1992, 66(11):6489-6495. 1357189.
12. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302(5647):1056-1060. 10.1126/science.1089591, 14564014.
13. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003, 9(11):1398-1403. 10.1038/nm946, 14528301.
14. Zhang W, Du J, Evans SL, Yu Y, Yu XF. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2011, 481(7381):376-379. 22190036.
15. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 2012, 481(7381):371-375.
16. Wang X, Zhang H, Lv M, Zuo T, Wu H, Wang J, Liu D, Wang C, Zhang J, Li X, Wu J, Yu B, Kong W, Yu X. Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-beta binding to Vif. Retrovirology 2013, 10(1):94. 10.1186/1742-4690-10-94, 23988114.
17. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003, 9(11):1404-1407. 10.1038/nm945, 14528300.
18. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 2004, 18(23):2861-2866. 10.1101/gad.1249904, 15574592.
19. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007, 81(15):8201-8210. 10.1128/JVI.00395-07, 17522216.
20. Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W, Yu XF. Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J Virol 2013, 87(3):1906-1911. 10.1128/JVI.02199-12, 23175372.
21. Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E, Gabuzda D. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 2007, 81(23):13235-13241. 10.1128/JVI.00204-07, 17898068.
22. Hultquist JF, McDougle RM, Anderson BD, Harris RS. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor beta on genetically distinct surfaces. AIDS Res Hum Retroviruses 2012, 28(12):1543-1551. 10.1089/aid.2012.0142, 22725134.
23. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 2006, 80(6):3112-3115. 10.1128/JVI.80.6.3112-3115.2006, 16501124.
24. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 2006, 281(25):17259-17265. 10.1074/jbc.M602413200, 16636053.
25. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu XF. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 2006, 349(2):290-299. 10.1016/j.virol.2006.02.002, 16530799.
26. Paul I, Cui J, Maynard EL. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci U S A 2006, 103(49):18475-18480. 10.1073/pnas.0604150103, 17132731.
27. Bergeron JR, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, Matthews SJ, Malim MH, Sanderson MR. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog 2010, 6(6):e1000925. 10.1371/journal.ppat.1000925, 20532212.
28. Stanley BJ, Ehrlich ES, Short L, Yu Y, Xiao Z, Yu XF, Xiong Y. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 2008, 82(17):8656-8663. 10.1128/JVI.00767-08, 18562529.
29. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. J Virol 2012, 86(5):2874-2877. 10.1128/JVI.06950-11, 22205746.
30. Schmitt K, Hill MS, Liu Z, Ruiz A, Culley N, Pinson DM, Stephens EB. Comparison of the replication and persistence of simian-human immunodeficiency viruses expressing Vif proteins with mutation of the SLQYLA or HCCH domains in macaques. Virology 2010, 404(2):187-203. 10.1016/j.virol.2010.04.017, 20627348.
31. Wang J, Zhang W, Lv M, Zuo T, Kong W, Yu X. Identification of a Cullin5-ElonginB-ElonginC E3 complex in degradation of feline immunodeficiency virus Vif-mediated feline APOBEC3 proteins. J Virol 2011, 85(23):12482-12491. 10.1128/JVI.05218-11, 21957297.
32. McNab T, Desport M, Tenaya WM, Hartaningsih N, Wilcox GE. Bovine immunodeficiency virus produces a transient viraemic phase soon after infection in Bos javanicus. Vet Microbiol 2010, 141(3-4):216-223. 10.1016/j.vetmic.2009.09.012, 19766411.
33. Van der Maaten MJ, Boothe AD, Seger CL. Isolation of a virus from cattle with persistent lymphocytosis. J Natl Cancer Inst 1972, 49(6):1649-1657. 4630608.
34. Whetstone CA, VanDerMaaten MJ, Black JW. Humoral immune response to the bovine immunodeficiency-like virus in experimentally and naturally infected cattle. J Virol 1990, 64(7):3557-3561. 2191153.
35. Kristbjornsdottir HB, Andresdottir V, Svansson V, Torsteinsdottir S, Matthiasdottir S, Andresson OS. The vif gene of maedi-visna virus is essential for infectivity in vivo and in vitro. Virology 2004, 318(1):350-359. 10.1016/j.virol.2003.09.044, 14972560.
36. Oberste MS, Gonda MA. Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes 1992, 6(1):95-102. 10.1007/BF01703760, 1312756.
37. Jonsson SR, Hache G, Stenglein MD, Fahrenkrug SC, Andresdottir V, Harris RS. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res 2006, 34(19):5683-5694. 10.1093/nar/gkl721, 17038330.
38. Jonsson SR, Andresdottir V. Host restriction of lentiviruses and viral countermeasures: APOBEC3 and Vif. Viruses 2013, 5(8):1934-1947. 10.3390/v5081934, 23903287.
39. Liu B, Yu X, Luo K, Yu Y, Yu XF. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 2004, 78(4):2072-2081. 10.1128/JVI.78.4.2072-2081.2004, 14747572.
40. Larue RS, Lengyel J, Jonsson SR, Andresdottir V, Harris RS. Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol 2010, 84(16):8193-8201. 10.1128/JVI.00685-10, 20519393.
41. Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999, 284(5413):455-461. 10.1126/science.284.5413.455, 10205047.
42. Hori T, Osaka F, Chiba T, Miyamoto C, Okabayashi K, Shimbara N, Kato S, Tanaka K. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 1999, 18(48):6829-6834. 10.1038/sj.onc.1203093, 10597293.
43. Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, Pierce JW, Podust VN, Luo RS, Chau V, Palombella VJ. Nedd8 modification of cul-1 activates SCF (beta (TrCP))-dependent ubiquitination of IkappaBalpha. Mol Cell Biol 2000, 20(7):2326-2333. 10.1128/MCB.20.7.2326-2333.2000, 10713156.
44. Kamura T, Maenaka K, Kotoshiba S, Matsumoto M, Kohda D, Conaway RC, Conaway JW, Nakayama KI. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 2004, 18(24):3055-3065. 10.1101/gad.1252404, 15601820.
45. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 1997, 94(6):2156-2161. 10.1073/pnas.94.6.2156, 9122164.
46. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J 2007, 21(1):217-222. 10.1096/fj.06-6773com, 17135358.
47. Krishna SS, Majumdar I, Grishin NV. Structural classification of zinc fingers: survey and summary. Nucleic Acids Res 2003, 31(2):532-550. 10.1093/nar/gkg161, 12527760.
48. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, Liu H, Yu Y, Zang Y, Yang M, Huang Z. Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by HIV-1 Vif. Nature 2014, 505(7482):229-233. 10.1038/nature12884, 24402281.
49. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, Gross JD. CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol Cell 2013, 49(4):632-644. 10.1016/j.molcel.2012.12.012, 23333304.
50. Wexler M, Sargent F, Jack RL, Stanley NR, Bogsch EG, Robinson C, Berks BC, Palmer T. TatD is a cytoplasmic protein with DNase activity. No requirement for TatD family proteins in sec-independent protein export. J Biol Chem 2000, 275(22):16717-16722. 10.1074/jbc.M000800200, 10747959.
51. Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One 2008, 3(12):e3963. 10.1371/journal.pone.0003963, 19088851.
52. Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K. Nedd8 on cullin: building an expressway to protein destruction. Oncogene 2004, 23(11):1985-1997. 10.1038/sj.onc.1207414, 15021886.